Roche Reports One-Year Benefits for Vamikibart in Eye Disease

Roche has announced positive one-year results from two Phase 3 clinical trials evaluating its investigational drug vamikibart for uveitic macular edema (UME), a serious eye condition that can lead to vision loss. The results showed sustained improvements in vision and reduced swelling in the retina after 52 weeks of treatment.

The findings come from the MEERKAT and SANDCAT studies, which compared vamikibart with a sham procedure designed to mimic an injection into the eye. The data were presented at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New Orleans, United States.

Across both studies, patients treated with vamikibart showed continued improvements in best-corrected visual acuity and reductions in central subfield thickness, a measure used to assess swelling in the macula. The macula is the central part of the retina responsible for detailed vision, including reading and recognising faces.

At 52 weeks, a numerically higher proportion of patients receiving vamikibart achieved an improvement of at least 15 letters in their vision compared with those receiving the sham procedure. The benefits observed earlier in the studies were also maintained over the one-year period.

Roche reported that the treatment was generally well tolerated, with a low incidence of treatment-related eye side effects and intraocular inflammation. The company also highlighted a low treatment burden. Around two-thirds of eligible patients did not require retreatment after the initial 16-week period, while most patients who needed further treatment received only one additional injection.

Alongside the clinical findings, the US Food and Drug Administration (FDA) has accepted Roche’s Biologics License Application (BLA) for vamikibart to treat UME. The FDA is expected to make a decision by July 2027. Regulatory applications have also been filed and accepted in the European Union, China and Japan.

“These one-year results strengthen vamikibart’s clinical profile, confirming that initial visual and anatomical improvements are maintained over 52 weeks,” said Levi Garraway, Roche’s chief medical officer and head of global product development. He said the regulatory progress brings the company closer to potentially offering a new treatment for people living with this sight-threatening condition.

Vamikibart is an investigational monoclonal antibody designed for injection into the eye. It targets interleukin-6 (IL-6), a protein involved in the inflammatory process that contributes to UME. By targeting this pathway, the treatment aims to reduce inflammation and help protect vision.

Uveitic macular edema develops when inflammation linked to uveitis causes fluid to build up in the macula. The condition can affect everyday activities such as reading and driving and may lead to lasting vision loss if not adequately treated.

Current treatments often rely on corticosteroids, which can help control inflammation but may cause side effects with long-term use, including cataracts and increased pressure inside the eye that can lead to glaucoma. A targeted non-steroid treatment could offer an alternative for patients who need longer-term disease management.

Nisha Acharya, professor of ophthalmology at the University of California, San Francisco, said vamikibart’s sustained improvements in vision and retinal structure could provide a potential new option for people with UME.

Vamikibart remains investigational and is not yet approved for routine use. If approved, Roche believes it could become the first targeted non-steroid treatment for UME, addressing an important unmet need in ophthalmology.

The results add to Roche’s efforts to develop treatments for retinal and inflammatory eye diseases. The upcoming FDA decision will be an important next step in determining whether vamikibart can become a new treatment option for patients at risk of vision loss.

You might also like